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Background: Tau is an axonal protein that binds to and regulates microtubule function. Hyper-phosphorylation
of Tau reduces its binding to microtubules and it is associated with β-amyloid deposition in Alzheimer’s disease.
Paradoxically, Tau reduction may prevent β-amyloid pathology, raising the possibility that Tau mediates intracellular
Aβ clearance. The current studies investigated the role of Tau in autophagic and proteasomal intracellular Aβ1-42
clearance and the subsequent effect on plaque deposition.
Results: Tau deletion impaired Aβ clearance via autophagy, but not the proteasome, while introduction of wild
type human Tau into Tau−/− mice partially restored autophagic clearance of Aβ1-42, suggesting that exogenous
Tau expression can support autophagic Aβ1-42 clearance. Tau deletion impaired autophagic flux and resulted in
Aβ1-42 accumulation in pre-lysosomal autophagic vacuoles, affecting Aβ1-42 deposition into the lysosome. This
autophagic defect was associated with decreased intracellular Aβ1-42 and increased plaque load in Tau−/− mice,
which displayed less cell death. Nilotinib, an Abl tyrosine kinase inhibitor that promotes autophagic clearance
mechanisms, reduced Aβ1-42 only when exogenous human Tau was expressed in Tau−/− mice.
Conclusions: These studies demonstrate that Tau deletion affects intracellular Aβ1-42 clearance, leading to
extracellular plaque.
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Two major pathologies that are linked to Alzheimer’s
disease (AD), include extracellular β-amyloid (Aβ) plaques
and intracellular neurofibrillary tangles (NFTs) comprised
of hyper-phosphorylated Tau (p-Tau) [1]. Although Aβ
peptides initially appeared to act upstream of Tau path-
ology in AD [2,3], more recent data suggest that Tau me-
diates Aβ toxicity since reduction of endogenous Tau
levels attenuates Aβ-induced neurodegeneration [4,5]. Tau
may be a critical mediator of Aβ toxicity in AD [6,7].
The level of insoluble p-Tau accumulation positively
correlates with neurodegeneration and cognitive decline
[8], suggesting that Tau dysfunction underlies dementia [9].
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unless otherwise stated.with no dementia or major cognitive decline [10,11], while
neocortical and hippocampal Aβ and Tau together are often
associated with dementia [12]. However, Tau mutations
or modifications are causal to some neurodegenerative
diseases without plaques, including fronto-temporal
dementia linked to chromosome 17 with Parkinsonism
(FTDP-17), progressive supranuclear palsy (PSP), and
corticobasal degeneration (CBD), suggesting Tau asso-
ciated neurodegeneration without Aβ deposition [6,7].
Taken together these findings suggest that Tau is a critical
regulator of Aβ1-42 toxicity through clearance of toxic
intracellular Aβ1-42 [13] and modulation of extracellular
plaque deposition, thus counteracting the toxic effects
of Aβ1-42. The interplay between Aβ and Tau suggests
that Tau mediates the development and progression of
neurodegeneration or it modulates Aβ clearance and
contributes to protection.
To evaluate whether Tau function affects intracellular Aβ
clearance and alters extracellular plaque formation, we usedal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Aβ1-42 clearance in wild type and Tau−/− mice. Intracellu-
lar Aβmay be cleared via autophagy and/or the proteasome
[14,15]. We previously demonstrated that lentiviral Aβ1-42
expression leads to p-Tau accumulation and inhibition of
both the proteasome and autophagy [13,14,16,17], while
the Abl tyrosine kinase inhibitor Nilotinib increases
autophagic Aβ and p-Tau clearance, leading to decreased
plaque levels in AD models [14,16]. Here we present
evidence in primary hippocampal neurons and in mouse
brain that Tau expression is critical for autophagic amyl-
oid clearance. Our data suggest that Tau deletion inhibits
autophagic flux, resulting in reduction of intracellular Aβ
degradation and increased plaque deposition.
Results and discussion
Autophagy and the proteasome contribute to p-Tau and
Aβ1-42 clearance
We previously demonstrated that impaired autophagic
clearance of intracellular Aβ leads to more plaque depos-
ition in parkin deficient mice [13,14,16,17]. To determine
the contribution of autophagic and proteasomal Aβ1-42
clearance with and without Tau over-expression, primary
neuronal hippocampus cultures were infected after 14 days
in vitro (DIV) with lentiviral constructs driving the expres-
sion of human Aβ1-42 or wild type (WT) human Tau for
24 hrs. We previously showed that Nilotinib promotes
autophagic clearance of Aβ1-42 [14,18]. To selectively
enhance autophagic protein clearance, neurons were
treated with 10 μM Nilotinib (or 1 μL DMSO) for 24 hrs
(all cells were treated with DMSO unless Nilotinib was
present). To inhibit autophagy, neurons were treated with
100 nM Bafilomycin-A1, and to block the proteasome
neurons were treated with 20 μM MG132 for 6 hrs. As
expected, Nilotinib significantly decreased human Aβ1-42
levels (Figure 1A, n = 5, p < 0.04) compared to DMSO
(1 μL). Nilotinib also significantly decreased Aβ1-42 levels
(Figure 1A, p < 0.05) when Tau was co-expressed with
Aβ1-42. No human (or mouse) Aβ1-42 was observed
when Tau was expressed alone. MG132 significantly
increased Aβ1-42 (n = 5, p < 0.043) compared to DMSO in
neurons expressing lentiviral Aβ1-42, indicating that some
Aβ1-42 is cleared via the proteasome. The combination of
Nilotinib and MG132 significantly reduced Aβ1-42 com-
pared to MG132 alone (p < 0.031), indicating that Aβ1-42
may be cleared via autophagy and/or the proteasome.
Nilotinib did not change Aβ1-42 levels in neurons co-
expressing Tau and Aβ1-42 in the presence of MG132,
but under these conditions (MG132 and Tau) Aβ1-42 was
significantly lower than MG132 (p < 0.03). Bafilomycin-A1
significantly increased Aβ1-42 (n = 5, p < 0.045) compared
to DMSO. In the presence of Bafilomycin-A1, Nilotinib
was unable to lower Aβ1-42 levels, further indicating that
Aβ1-42 is partially cleared through autophagy.We previously reported that lentiviral Aβ1-42 expression
leads to elevation of p-Tau in the rat cortex [13,14]. To
determine whether autophagic blockade and/or protea-
somal inhibition affect amyloid secretion, we measured
Aβ1-42 and/or Tau in cell extracts (STEN buffer) and
media. Lentiviral expression of human Aβ1-42 in primary
mouse hippocampal neurons led to a significant increase in
soluble and secreted (media) Aβ1-42 (Figure 1B, p < 0.001,
n = 5) at 24 hrs compared to 12 hrs post-infection. Pro-
longed expression of lentiviral Aβ1-42 for 48 hrs resulted in
lower levels of soluble and media Aβ1-42 compared to
24 hrs, but remained higher than 12 hrs (p < 0.01). The
level of Ser 396 p-Tau was increased (Figure 1C, p < 0.001,
n = 5) with a concomitant increase in media p-Tau
(Figure 1C, p < 0.05, n = 5) when Aβ1-42 was expressed
for 24 hrs compared to 12 hrs, indicating that Aβ1-42
expression triggers murine p-Tau. p-Tau levels were
further increased (p < 0.0001, n = 5) at 48 hrs, suggest-
ing progressive accumulation of p-Tau in response to
Aβ1-42.
Because of the observed effects of Aβ1-42 on p-Tau, we
also measured p-Tau in cell extracts via ELISA in parallel
with Aβ1-42 as shown in Figure 1A. Nilotinib prevented
Aβ1-42-induced p-Tau (Figure 1D, n = 5, p < 0.03) com-
pared to DMSO (1 μL). Lentiviral expression of human
WT Tau and Aβ1-42 together (DMSO) increased p-Tau
(Figure 1D, n = 5, p < 0.03) compared to Aβ1-42 alone but
Nilotinib reversed p-Tau (Figure 1D, p < 0.04) back to the
level of Aβ1-42 expression alone.
Proteasome inhibition (MG132) increased p-Tau in
LacZ infected cells (Figure 1D, n = 5, p < 0.05) or in the
presence of Aβ1-42 (+DMSO). However, Nilotinib pre-
vented p-Tau accumulation even in the presence of
MG132 in Aβ1-42 expressing cells (n = 5, p < 0.036).
Nilotinib also reduced p-Tau (Figure 1D, n = 5, p < 0.03)
in cells co-expressing Tau and Aβ1-42 together, further
suggesting that autophagy co-operates with the proteasome
to clear p-Tau. MG132 significantly increased p-Tau in Tau
expressing cells (p < 0.001).
Bafilomycin-A1 robustly increased p-Tau in Aβ1-42
(+DMSO) infected cells (Figure 1D, n = 5, p < 0.034) and
Nilotinib had no effect on p-Tau with Bafilomycin-A1.
Lentiviral expression was verified by Western blots (WB)
showing equal levels of V5 lentiviral tag (Figure 1D insert,
1st blot) in cells expressing lentiviral human Aβ1-42
(2nd blot) or human Tau (3rd blot) compared to total
Tau levels (4th blot) relative to actin (5th blot). The
ELISA results of Tau metabolism were confirmed with
WB using AT8 antibody (Figure 1E, n = 4). Tau or Aβ
significantly (p < 0.05) increased p-Tau compared to
LacZ (1st blot) or in the presence of MG132 (3rd blot)
or Bafilomycin-A1 (5th blot) relative to actin. Nilotinib
reduced p-Tau relative to actin (1st blot, p < 0.05) when
Aβ1-42 and Tau were expressed together or separately
Figure 1 (See legend on next page.)
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Figure 1 Inhibition of the proteasome or autophagy partially affects Aβ1-42 and p-Tau clearance. To dissect out the contribution of the
proteasome from autophagy-lysosome in amyloid clearance, primary hippocampal neurons (DIV14) were infected with lentivirus plasmids, and
then treated with 1 μl DMSO or autophagy modulators (Nilotinib or Bafilomycin-A1) and/or proteasome inhibitor (MG132). Histograms represent
ELISA concentrations of A) Aβ1-42 and time course showing the distribution of intracellular and media B) Aβ1-42 and C) p-Tau Ser 396. D) p-Tau
Ser 396 in the presence of modulators of autophagy and the proteasome. Insert). WB analysis on 4-12% NuPAGE SDS gel showing expression of
the lentiviral tag V5, Aβ1-42, human Tau (HT7) and total Tau relative to actin. E) WB analysis on 10% NuPAGE SDS gel showing AT8 levels relative
to actin. F) Histograms represent 20S proteasome activity assay in human M17 neuroblastoma cells. G) RT-PCR showing the effects of Nilotinib on
lentiviral gene expression relative to GAPDH. # indicates significantly different to LacZ, Asterisk is significantly different to Aβ1-42 + DMSO or as
indicated, bars are mean ± SEM, two-way ANOVA.
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A1 blocked the effects of Nilotinib on p-Tau reduction.
To further determine the effects of Aβ1-42 and p-Tau
on proteasome activity, a chymotrypsin-like assay in
M17 neuroblastoma showed that Aβ1-42 (with DMSO)
significantly decreased proteasomal function (Figure 1F,
n = 6, p < 0.001) compared to LacZ (DMSO), but Nilotinib
partially reversed Aβ1-42 effects on proteasome function
(p < 0.01) in cells expressing Aβ1-42 alone or together
with Tau. Tau did not affect proteasomal function, but Tau
and Aβ1-42 together significantly reduced proteasome
activity (p < 0.04) compared to Tau or LacZ. MG132 com-
pletely inhibited the proteasome. However, Bafilomycin-
A1 did not affect proteasomal activity in control (LacZ)
or Tau expressing cells, but significantly decreased it in
Aβ1-42 expressing cells with and without Tau, further
suggesting that lack of Aβ1-42 clearance affects prote-
asome activity. The effects of Nilotinib on lentiviral human
Aβ1-42 and Tau expression were verified by RT-PCR using
the same primers that were utilized to clone Aβ1-42
and Tau into the lentivirus as we previously described
[13,15,19]. Nilotinib did not affect Aβ1-42 (Figure 1G,
top blot) and Tau (Figure 1G, bottom blot) RNA levels
compared to DMSO relative to GAPDH, suggesting
that Nilotinib does not alter lentiviral expression.
Tau is required for autophagic amyloid clearance
To focus on the effects of Tau deletion on intracellular
Aβ1-42 clearance, we tested our model in WT and
Tau−/− mouse primary hippocampal neurons in vitro.
Mouse hippocampal neurons were prepared from C57BL/
6 (WT) and homozygous Tau−/− mice [20,21] and infected
with the lentiviral clones at DIV14. Nilotinib reduced the
levels of Aβ1-42 in Tau−/− neurons (compared to DMSO,
p < 0.047) and in cells expressing Aβ1-42 and Tau together
(Figure 2A, n = 5, p < 0.032). Interestingly, Aβ1-42 and
Tau together (+DMSO) reduced Aβ1-42 levels (p < 0.042)
compared to Aβ1-42 alone (+DMSO) and Nilotinib fur-
ther decreased Aβ1-42 (Figure 2A, p < 0.035), suggesting
that Tau expression partially increases Aβ1-42 clearance.
MG132 blocked Nilotinib-induced Aβ1-42 clearance in
Tau−/− neurons, but Tau expression reduced Aβ1-42 levels
(p < 0.037). No Aβ1-42 was detected in Tau expressing
Tau−/− primary neurons. Bafilomycin-A1 increased Aβ1-42 levels (p < 0.05) and Nilotinib did not reverse these
effects in Tau−/− neurons, but Tau expression reduced
Aβ1-42 back to DMSO levels (p < 0.05), further suggesting
that Tau expression enhances amyloid clearance. No
p-Tau was detected in Aβ1-42 expressing Tau−/− neurons,
but Nilotinib significantly (Figure 2B, n = 5, p < 0.05)
reduced p-Tau compared to DMSO in Tau alone or with
Aβ1-42. MG132 increased p-Tau levels (p < 0.03) even in
the presence of Nilotinib when Tau was expressed alone
or together with Aβ1-42. However, both MG132 and
Bafilomycin-A1 blocked Nilotinib-induced p-Tau decrease
(p < 0.01) in the presence of Tau alone or together with
Aβ1-42. Together, these data suggest that Tau is required
for complete amyloid clearance.
These results were also conducted in vivo in WT
(C57BL/6) and Tau−/− mice, which are relevant to our
experiments because organelle movement was reported
to be impaired in these mice [20,21], which my potentially
affect autophagosome movement. Mice were stereotaxically
injected into the hippocampus with V5-tagged lentiviral
constructs driving human Tau and Aβ1-42 expression and
adjusted with LacZ to 1×106 multiplicity of infection
(MOI). Animals were treated 3 weeks post-injection with
daily 10 mg/kg intraperotineal (I.P) injection of Nilotinib
or 30 μL DMSO once a day for 3 (additional) consecutive
weeks as we previously reported [14,16]. To verify equal
expression of lentiviral clones, 20 μm thick coronal brain
sections were co-stained for human specific Aβ1-42,
p-Tau and V5 as shown in Additional file 1: Figure S1.
No human (or mouse) Aβ1-42 was detected by ELISA
in human Tau expressing WT mice (Figure 2C, n = 4),
but Nilotinib reduced Aβ1-42 levels when Aβ1-42 was
expressed alone (p < 0.0001) or together with human
Tau (p < 0.001). Human Aβ1-42 was significantly higher
(p < 0.01) in Aβ1-42 expressing Tau−/− mice compared to
Aβ1-42 expressing WT mice (Figure 2C, n = 4). Nilotinib
failed to reduce Aβ1-42 levels in Tau−/− mice compared to
WT, but introduction of lentiviral human WT Tau with
Aβ1-42 into Tau−/− mice significantly reduced Aβ1-42
(p < 0.05) compared to Aβ1-42 alone. These data suggest
that exogenous human Tau facilitates autophagic Aβ1-42
clearance. It is important to note that no changes were
observed with mouse Aβ1-42 when lentiviral human Tau
or Aβ1-42 were expressed in WT or Tau−/− mice (data
Figure 2 (See legend on next page.)
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Figure 2 Tau deletion impairs autophagic clearance. Primary hippocampal neurons from WT and Tau−/− mice were infected with lentivirus
plasmids and then treated with 1 μl DMSO or autophagy modulators (Nilotinib or Bafilomycin-A1) and/or proteasome inhibitor (MG132). Histograms
represent ELISA concentrations of soluble and insoluble brain extracts of A) human Aβ1-42 and B) p-Tau Ser 396. WT (C57BL/6) and Tau−/− mice were
injected with 1×106 multiplicity of infection (MOI) of lentiviral human Tau, Aβ1-42, Tau ± Aβ1-42 and adjusted with LacZ. All animals were treated
3 weeks post-injection with daily 10 mg/kg IP injection or 30 μL DMSO once a day for 3 (additional) consecutive weeks. Histograms represent ELISA
concentrations of total brain extracts of C) human Aβ1-42 and D) p-Tau Ser 396. Asterisk is significantly different to Aβ1-42 + DMSO or as indicated,
# indicates significantly different to Aβ1-42 + DMSO in WT mice. Bars are mean ± SEM, two-way ANOVA.
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cleaving enzymes [14], indicating no changes in APP
processing.
The effects of Nilotinib on p-Tau clearance were also
examined. Nilotinib reduced p-Tau (Figure 2D, n = 4,
p < 0.01) in Tau over-expressing WT mice and when
Tau and Aβ1-42 were expressed together (p < 0.015),
which led to more p-Tau than Tau alone (p < 0.02).
However, p-Tau was significantly lower (Figure 2D, n = 4,
p < 0.037) in human Tau expressing Tau−/− compared to
WT mice, and although Aβ1-42 together with Tau signifi-
cantly increased p-Tau in Tau−/− mice (p < 0.04), p-Tau
remained significantly lower (p < 0.05) in Tau−/− compared
to WT mice. Nilotinib did not change p-Tau when human
Tau was expressed alone in Tau−/− mice, but it signifi-
cantly reduced it (p < 0.03) when Aβ1-42 and Tau were
co-expressed.
Tau deletion impairs autophagic flux in mouse brain
To determine autophagic flux, mouse brain tissues were
fractionated to isolate autophagic vacuoles (AVs), which
were identified by light chain protein-3 (LC3) that indi-
cates pre-lysosomal autophagosome formation (Figure 3A,
insert) as we previously indicated [14,16]. Lysosome
associated membrane protein (LAMP)-2a was used as a
marker of the lysosomal fraction (Figure 3A, n = 4).
Mitochondrial cytochrome c oxidase (COX)-IV was also
used as another control marker. ELISA measurement
of Aβ1-42 in AVs in WT mice expressing Aβ1-42
showed Aβ1-42 accumulation in AV10 (Figure 3A, n = 4)
and AV20 (Figure 3B, n = 4) but not in the lysosome
(Figure 3C, n = 4). Nilotinib significantly reduced Aβ1-
42 in AV10 (Figure 3A, n = 4, p < 0.001) and increased it
in the lysosome (Figure 3C, p < 0.0001), suggesting that
Nilotinib facilitates autophagic flux from autophagosomal
vacuoles to the lysosome [22]. In WT mice expressing
Aβ1-42 and Tau together, Nilotinib significantly reduced
Aβ1-42 in AV10 (Figure 3A, n = 4, p < 0.01) and increased
it in AV20 (Figure 3B, p < 0.04). In Aβ1-42-expressing
Tau−/− mice, Aβ1-42 was significantly higher in AV10
(Figure 3A, n = 4, p < 0.03) and unchanged in AV20
(Figure 3B) or lysosomes (Figure 3C) compared to WT.
Nilotinib did not alter Aβ1-42 levels in AVs in Tau−/−
mice, suggesting that Tau deletion affects flux through
deposition of autophagosomal contents into the lysosomes.However, Nilotinib decreased Aβ1-42 in AV20 (Figure 3A,
p < 0.05) and increased it in the lysosomes (Figure 3C,
p < 0.001) when lentiviral Tau was co-expressed with
Aβ1-42 in Tau−/− mice, indicating that exogenous Tau
restores Aβ1-42 clearance.
Further ELISA measurement of Ser396 p-Tau showed
significantly high levels of p-Tau in AV10 (Figure 3D,
n = 4, p < 0.0001) and AV20 (Figure 3E, p < 0.001) in
Aβ1-42 expressing WT mice compared to LacZ (+DMSO),
but Nilotinib reduced p-Tau in AV10 (Figure 3D, p < 0.001)
and increased it in the lysosomes (Figure 3F, p < 0.001).
Expression of Aβ1-42 together with Tau in WT mice
significantly increased p-Tau in AV10 (Figure 3D, n = 4,
p < 0.001) compared to Aβ1-42 alone, but Nilotinib again
reduced p-Tau in AV10 (p < 0.03) and increased it in
AV20 (Figure 3E, p < 0.03). Nilotinib also reduced p-Tau
in AV10 (Figure 3D, p < 0.03) and AV20 (Figure 3E,
p < 0.04) in Tau expressing WT mice. Lentiviral Tau
expression led to detection of p-Tau in AV10 (Figure 3D)
and AV20 (Figure 3E) but not in the lysosomes in Tau−/−
mice and Nilotinib did not alter p-Tau levels, suggesting
that exogenous Tau may not affect autophagic p-Tau
clearance. However, when Tau was co-expressed with
Aβ1-42 in Tau−/− mice, Nilotinib significantly decreased
p-Tau in AV10 (Figure 3D, p < 0.01) and AV20 (Figure 3E,
p < 0.05) and increased it in lysosomes (Figure 3F, p <
0.001), indicating that exogenous Tau affects Aβ1-42 and
p-Tau clearance in Tau−/− mice.
We previously demonstrated an effect for parkin and
Nilotinib on autophagic Aβ1-42 clearance [14,16], so we
used lentiviral parkin expression as a control for Nilotinib
to show markers of autophagic changes. WB of total brain
lysates shows equal V5 levels (Figure 3G, n = 5) in WT
mice, indicating equal expression of lentiviral clones.
Human Tau (HT7) was only detected in WT mice
expressing human Tau (Figure 3G) and was decreased
in the presence of parkin or Nilotinib (n = 5, p < 0.05),
in agreement with ELISA. However, total Tau (Tau-5)
and p-Tau (AT8) were increased in Tau (n = 5, p < 0.05)
and Tau and Aβ1-42 (p < 0.05) expressing WT mice,
but both parkin and Nilotinib decreased p-Tau (38 and
50%, respectively, p < 0.04) relative to actin. Nilotinib
significantly decreased p-Tau at Ser262 (44%) and Ser
396 (53%) relative to actin in Aβ1-42 alone or with Tau
in WT mice (Figure 3H, n = 5, p < 0.05).
Figure 3 (See legend on next page.)
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Figure 3 Boosting autophagy leads to Aβ1-42 clearance in WT but not Tau−/− mice. WT and Tau−/− mice were injected with lentiviral Tau
± Aβ1-42 for 3 weeks and treated I.P. with 10 mg/kg Nilotinib or DMSO once a day for 3 weeks. Brain tissues were fractionated to isolate AVs and
human specific ELISA was performed. Histograms represent concentration of A) Aβ1-42, insert is WB on 4-12% SDS NuPAGE gel showing LC3 and
LAMP-2a as AV markers, B) Aβ1-42 in AV20, and C) Aβ1-42 in lysosomal fractions in WT and Tau−/− mice. ELISA concentrations of Ser 396 Tau in
D) AV10, E) AV20, and F) lysosomal fractions in WT and Tau−/− mice. WB analysis on 4-12% SDS NuPAGE gel of total brain extracts from WT mice
showing G) V5 to verify equal expression of all lentiviruses, human Tau (HT7), total Tau, AT8 and AT180 relative to actin. H) shows p-Tau Ser 262,
Ser 396 and autophagic markers Beclin-1 and LC3-I/II relative to actin. WB analysis on 4-12% SDS NuPAGE gel of total brain extracts from Tau−/−
mice showing I) V5, human Tau (HT7), total Tau, AT8, and AT180 relative to tubulin. J) shows p-Tau Ser 262, Ser 396 and autophagic markers
Beclin-1, LC3-I and LC3-II relative to actin. Asterisk indicates significantly different to Aβ1-42 + DMSO, bars are mean ± SEM, two-way ANOVA.
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1 compared to LacZ relative to actin (Figure 3H and
Additional file 1: Figure S1 1 M, n = 5), but Nilotinib
and parkin increased Beclin-1 levels (40% and 51%,
respectively, p < 0.05) relative to actin when Aβ1-42
was expressed alone or together with Tau (Figure 3H and
Additional file 1: Figure S1 1 M, n = 5). No significant
changes in LC3-I levels (Figure 3H and Additional file 1:
Figure S1 1 M, n = 5) were detected in WT mice but LC3-
II was increased in Tau (100%) or Tau and Aβ1-42 (44%)
relative to LC3-I or actin (Figure 3H and Additional file 1:
Figure S1 1 M, n = 5, p < 0.001). LC3-II disappeared in
Nilotinib and parkin mice, suggesting enhanced autophago-
some clearance. Equal V5 levels (Figure 3I, n = 5) were also
detected in Tau−/− mice, and human Tau (HT7) was only
detected in lentiviral Tau expressing Tau−/− mice (Figure 3I)
and disappeared in the presence of parkin or Nilotinib
(n = 5). Total Tau (Tau-5) and p-Tau (AT8) were detected
in Tau expressing mice but both parkin and Nilotinib
cleared p-Tau relative to tubulin. Nilotinib eliminated
Ser262 and Ser 396 p-Tau when Aβ1-42 was expressed
alone or with Tau in Tau−/− mice (Figure 3J, n = 5, p <
0.05). Tau expression decreased Beclin-1 compared to
LacZ relative to actin (n = 5) but Nilotinib and parkin
increased Beclin-1 (35% and 59%, respectively, p < 0.05)
relative to actin levels when Aβ1-42 was expressed alone or
together with Tau (Figure 3J and Additional file 1: Figure S1
1 M, n = 5). LC3-II significantly increased in Tau (58%)
alone or with Aβ1-42 (48%) relative to LC3-I (n = 5, p <
0.05). LC3-II was reversed back to LacZ with Nilotinib and
parkin, suggesting autophagosome clearance.
Nilotinib reduces p-Tau when exogenous Tau is expressed
in Tau−/− mice
We determined whether introduction of exogenous Tau
affects p-Tau clearance in WT and Tau−/− mice treated
with Nilotinib. Labeling with AT8 and 3, 3’-diaminoben-
zidine (DAB) counterstaining shows endogenous p-Tau
in the hippocampus of WT mice injected with a lenti-
virus driving LacZ expression (Figure 4A, n = 4, insert
shows higher magnification). Human WT Tau increased
(Figure 4U, 82%, by stereology, insert is higher magnifi-
cation) p-Tau (Figure 4B, n = 5, p < 0.02) in WT mice
treated with DMSO but Nilotinib (Figure 4C, insert ishigher magnification) eliminated p-Tau (n = 5). Aβ1-42
and Tau together (Figure 4D, insert is higher magnifi-
cation) increased p-Tau (Figure 4U, 82%, by stereology,
p < 0.02) compared to LacZ but Nilotinib (Figure 4E)
decreased p-Tau (Figure 4U, 35% higher than control,
p < 0.04) in WT mice. No p-Tau was observed in the
hippocampus of Tau−/− mice (Figure 4F, insert is high
magnification) but human Tau expression (Figure 4G,
insert is higher magnification) led to p-Tau in Tau−/−
mice with DMSO, while Nilotinib reduced (Figure 4U, 41%,
n = 5, p < 0.05) p-Tau (Figure 4H, insert is higher magnifi-
cation). Co-expression of Aβ1-42 and Tau (Figure 4J,
insert is higher magnification) increased p-Tau that was
not different than Tau alone (Figure 4I) but Nilotinib
reduced (19%) p-Tau (Figure 4J, n = 5, insert is higher
magnification) compared to DMSO. Injection of lentiviral
Tau into the hippocampus also increased p-Tau (AT180)
(91%, by stereology) in the cortex in mice (Figure 4L,
n = 5, p < 0.03) treated with DMSO compared to LacZ
(Figure 4K), but Nilotinib (Figure 4M, n = 5) reduced
p-Tau (45%, p < 0.05). Aβ1-42 and Tau together (Figure 4N,
n = 5) increased p-Tau levels (69%, by stereology, p < 0.04)
compared to LacZ but Nilotinib (Figure 4O) decreased
p-Tau (62% by stereology, p < 0.04) in WT mice. No p-Tau
was observed in the cortex of Tau−/− mice (Figure 4P) but
human Tau expression (Figure 4Q) increased p-Tau in
Tau−/− mice with DMSO, while Nilotinib reduced (56%,
n = 5, p < 0.05) p-Tau (Figure 4R) compared to DMSO
(Figure 4Q). Co-expression of Aβ1-42 and Tau increased p-
Tau (Figure 4S, 29%) compared to Tau alone and Nilotinib
significantly reduced p-Tau levels (Figure 4T, n = 5, 31%,
p < 0.05) compared to DMSO (Figure 4U) in Tau−/− mice.
Tau deletion reduces intracellular Aβ1-42 and contributes
to plaque formation
We determined whether Tau deletion affects the distri-
bution of intracellular and extracellular Aβ1-42. Plaque
deposition was observed in the hippocampus of WT mice
expressing Aβ1-42 at 1 month post-injection (Figure 5A,
n = 5). Nilotinib significantly decreased (by stereology)
intracellular Aβ1-42 (Figure 5B and U, n = 5, p < 0.01),
which was also verified with human specific Aβ1-42 anti-
body staining as shown in Additional file 1: Figure S1.
Nilotinib reduced plaque load (Figure 5B and V, p < 0.001)
UFigure 4 (See legend on next page.)
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Figure 4 Aβ1-42 is more efficiently cleared in WT than Tau−/− mice. Staining of 20 μm thick coronal sections with p-Tau (AT8) and counterstained
with DAB in A) LacZ +DMSO, B) Tau +DMSO, C) Tau +Nilotinib, D) Tau and Aβ1-42 +DMSO and E) Tau and Aβ1-42 +Nilotinib. Staining of hippocampus
with AT8 and DAB in F) LacZ +DMSO, G) Tau +DMSO, H) Tau +Nilotinib, I) Tau and Aβ1-42 +DMSO and J) Tau and Aβ1-42 +Nilotinib in Tau−/− mice.
Staining of 20 μm thick coronal sections with p-Tau (AT180) and DAB in K) LacZ +DMSO, L) Tau +DMSO, M) Tau +Nilotinib, N) Tau and Aβ1-42 +DMSO
and O) Tau and Aβ1-42 +Nilotinib in WT mice. Staining of cortical sections in P) LacZ +DMSO, Q) Tau +DMSO, R) Tau +Nilotinib, S) Tau and Aβ1-42 +
DMSO and T) Tau and Aβ1-42 + Nilotinib in Tau−/− mice. U) Histograms represent stereological quantification of p-Tau. Asterisk indicates significantly
different to Aβ1-42 + DMSO, bars are mean ± SEM, two-way ANOVA.
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pressing Aβ1-42 alone, consistent with our previously pub-
lished data [14,23]. Tau and Aβ1-42 increased plaque levels
(Figure 5C and V, n = 5, p < 0.02) in WT mice treated with
DMSO and Nilotinib significantly decreased intracellular
Aβ1-42 (Figure 5D and U, p < 0.02) and plaque load
(Figure 5D and V, p < 0.001) compared to Aβ1-42 alone or
LacZ (Figure 5E and U, p < 0.001, n = 5). Nilotinib did not
alter intracellular Aβ1-42 staining (Figure 5G and U, n = 5)
or plaque load (Figure 5G and V) in the hippocampus of
Tau−/− mice compared to DMSO (Figure 5F, n = 5), which
displayed more plaque (Figure 5F and V, p < 0.001, n = 5)
and less intracellular Aβ1-42 (Figure 5F and U, p < 0.001)
Aβ compared to WT mice (Figure 5A). Tau expression
with Aβ1-42 in Tau−/− mice increased intracellular Aβ1-
42 (Figure 5H and U, p < 0.01, n = 5) and decreased plaque
levels (Figure 5H and V, p < 0.05) while Nilotinib reversed
intracellular Aβ1-42 (Figure 5I and U, p < 0.001) and
plaque (Figure 5I and V, p < 0.001) back to WT levels
(Figure 5D). No Aβ1-42 staining was observed in mice
expressing LacZ (Figure 5J). Plaque deposition and intra-
cellular Aβ1-42 were also detected in the cortex of WT
mice expressing Aβ1-42 alone (Figure 5K) or together
with Tau (Figure 5M) while Nilotinib reduced Aβ1-42
staining (Figure 5L and N) compared to DMSO (Figure 5K
and I) and LacZ (Figure 5O, n = 5). Plaque deposition
was higher in the cortex of Tau−/− mice expressing Aβ1-
42 alone (Figure 5P) or together with Tau (Figure 5R)
while Nilotinib reduced Aβ1-42 staining only when Tau
was introduced (Figure 5S) compared to Aβ1-42 alone
(Figure 5Q and I) and LacZ (Figure 5T, n = 5).
Tau deletion attenuates Aβ1-42-induced cell death despite
the increase in plaque load
To determine whether Tau deletion affects cell viability
in parallel with the distribution of intracellular and
plaque Aβ1-42, cell death was assessed via silver staining
that detects degenerating fibers and neurons and caspase-3
activity. Aβ1-42 expression (+DMSO) increased the num-
ber of silver-positive cells (Figure 6A and K, n = 5, p < 0.05)
compared to LacZ (Figure 6E and K) in WT mice and
Nilotinib eliminated cell death (Figure 6B). An increase in
silver-stained cells was detected when Tau was expressed
together with Aβ1-42 (Figure 6C and K, n = 5, p < 0.05)
and again Nilotinib reduced cell death (Figure 6D and K)in WT mice. In Tau−/− mice, Aβ1-42 (+DMSO) also in-
creased the number of silver-positive cells (Figure 6F and
K, n = 5, p < 0.05) compared to LacZ (Figure 6J and K)
but this increase remained significantly lower than WT
(Figure 6A and K, p < 0.05), suggesting that Tau deletion
attenuates Aβ1-42 toxicity. In contrast with WT mice,
Nilotinib did not reduce Aβ1-42-induced cell death in
Tau−/− mice (Figure 6G). Exogenous Tau and Aβ1-42
together increased cell death (Figure 6H and K, n = 5,
p < 0.01), which remained lower than WT (Figure 6A) but
Nilotinib completely reversed cell death (Figure 6I and
K), indicating that Tau is needed to mediate autophagic
clearance and reduce Aβ1-42 toxicity. Caspase-3 activ-
ity was also increased in WT mice expressing Aβ1-42
alone or together with Tau (Figure 6L, n = 5, p < 0.025)
but Nilotinib reversed these effects. Although Aβ1-42
increased caspase-3 activity with and without Tau
(Figure 6L, n = 5, p < 0.05), Nilotinib reversed these
effects only when Tau was co-expressed with Aβ1-42.
Discussion
These studies demonstrate that autophagic intracellular
Aβ1-42 clearance requires Tau, suggesting that normal
Tau function modulates plaque deposition via regulation
of intracellular Aβ1-42 degradation. Inhibition of either
the proteasome or autophagy led to partial Aβ1-42 and
p-Tau clearance, suggesting that Aβ1-42 and p-Tau may
be degraded via either autophagy and/or the proteasome.
Tau deletion impaired intracellular Aβ clearance and
increased extracellular plaque formation, while intro-
duction of human Tau into Tau−/− brains restored autoph-
agic Aβ1-42 and p-Tau clearance and reduced plaques.
We previously demonstrated that the E3 ubiquitin ligase
parkin is essential for Nilotinib-induced autophagic amyl-
oid clearance [14]. However, parkin and Tau differentially
alter autophagic flux. Parkin deletion affects the transfer
of Aβ1-42 and p-Tau from pre-lysosomal AVs, suggesting
impairment of the earlier steps of the sequestration
process [14,16]. Tau deletion affects the deposition of
amyloids from AVs into the lysosomes, indicating that
Tau is required for the completion of autophagic clear-
ance. However, impairment of autophagic flux with either
Tau or parkin deletion leads to plaque deposition, further
suggesting that reduction of intracellular Aβ1-42 clearance
may lead to its secretion. Nilsson et al. [24] recently
U V
Figure 5 (See legend on next page.)
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Figure 5 Increased Aβ1-42 plaque deposition in Tau−/− mice. Staining of 20 μm thick coronal sections with 6E10 and DAB in wild type mice
injected with lentiviral A) Aβ1-42 +DMSO, B) Aβ1-42 +Nilo, C) Aβ1-42 + Tau +DMSO, D) Aβ1-42 + Tau +Nilo and E) LacZ +DMSO in the hippocampus.
Staining of 20 μm thick coronal sections with 6E10 and DAB in Tau−/− mice injected with lentiviral F) Aβ1-42 +DMSO, G) Aβ1-42 +Nilo, H) Aβ1-42 + Tau +
DMSO, I) Aβ1-42 + Tau +Nilo and J) LacZ +DMSO in the cortex. Staining of 20 μm thick coronal sections with 6E10 and DAB in wild type mice injected
with lentiviral K) Aβ1-42 + DMSO, L) Aβ1-42 + Nilo, M) Aβ1-42 + Tau + DMSO, N) Aβ1-42 + Tau + Nilo and O) LacZ + DMSO in the cortex. Staining of
20 μm thick coronal sections with 6E10 and DAB in Tau−/− mice injected with lentiviral P) Aβ1-42 + DMSO, Q) Aβ1-42 + Nilo, R) Aβ1-42 + Tau +
DMSO, S) Aβ1-42 + Tau + Nilo and T) LacZ + DMSO in the cortex. Histograms represent U) stereological counting of Aβ1-42 positive cells and V)
plaque number/mm2 in total brain. Asterisk is significantly different to control (Aβ1-42 + DMSO) or as indicated, bars are mean ± SEM, two-way ANOVA.
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AD mouse diminishes extracellular Aβ release, increases
its intracellular level and reduces extracellular amyloid
plaque. Our results suggest that Tau deletion reduces
intracellular Aβ level and increases plaque build-up.
Nilsson et al. [24] model inhibited autophagy at an early
pre-autophagosomal level where an ubiquitin-like reac-
tion involving ATGs triggers autophagy, leading to
autophagosome formation and subsequent maturation
[22]. Our model demonstrated impairment of autophagic
flux at a later pre-lysosomal stage, where Aβ and/or Tau
have already accumulated in autophagosomes without
deposition into the lysosomes. Thus, Aβ release and
plaque formation may depend on the type of impairment
along the autophagic cascade, suggesting that pre-
autophagosomal inhibition of flux results in intracellular
accumulation and less Aβ secretion whereas arrest of
autophagic flux after Aβ deposition in undigested autop-
hagosomes leads to Aβ secretion and plaque formation.
Tau maybe required to facilitate autophagosome matur-
ation and retrograde transport from distal axons towards
cell bodies to fuse with lysosomes [25], thus contributing
to modulation of autophagic flux. Our data suggest that
Tau deletion reduces intracellular Aβ degradation [14],
which may be due in part to axonal changes that affect
efficient autophagosome fusion with the lysosome in
the Tau−/− mouse, which is reported to have impaired
organelle movement [20,21]. The normal role of Tau in
autophagy was shown in cellular models of Niemann-Pick
type C (NPC) disease showing that acute reductions of
Tau in NPC1-deficient fibroblasts impairs autophagy [26].
As autophagy is up-regulated in NPC and protein degrad-
ation may depend on movement along microtubules,
Tau knockdown aggravates NPC pathology through a
mechanism independent of Tau aggregation [27] as is
often observed in neurodegenerative diseases, further
suggesting a critical role for normal Tau in the regulation
of autophagy. Taken together these data raise the possibil-
ity that loss of Tau function via mutations, deletion or
hyper-phosphorylation may lead to decreased Tau binding
to microtubules and subsequent impairment of auto-
phagic flux, which may alter the distribution of intracellu-
lar and extracellular Aβ1-42 overtime. Tau may affect
autophagic flux via interaction with autophagy enzymes,including Beclin-1 and the microtubule associated protein
A/B light chain (MAPA/BLC)-3. We previously showed
that p-Tau co-localizes with LC3 in rat brains expressing
WT or mutant P301L Tau [28] and the elucidation of
the molecular mechanisms underlying interaction be-
tween Tau and autophagy proteins is an area for future
investigation.
A number of studies suggested that facilitation of Tau
clearance via up-regulation of the proteasome or autophagy
can protect cells from age-related stress [29,30]. Previous
studies showed that impaired autophagy may affect protea-
somal activity [31], but the interplay between autophagy
and the proteasome may not be a simple compensatory
relationship. Our studies show that loss of normal Tau
function via deletion impairs autophagic flux, independent
of proteasomal activity. We demonstrated that intro-
duction of WT Tau into Tau−/− mice partially restores
autophagic Aβ1-42 clearance, indicating that exogenous
human Tau expression may affect Aβ1-42 levels. Expres-
sion of exogenous Tau may restore Aβ1-42 clearance due
to possible integration of Tau into microtubules, leading
to facilitation of autophagy. However, the relationship
between Aβ and Tau is contentious with more recent
in vivo reports demonstrating that Tau deletion prevents
Aβ toxicity, and previous cell culture studies showing that
Aβ triggers Tau pathology (reviewed in [32]). Our data
show that Tau deletion exacerbates extracellular plaque
build-up but attenuates cell death, indicating that Tau may
modulate Aβ1-42 toxicity via alteration of intracellular and
extracellular Aβ1-42 levels. Clinically, some aged human
brains have plaques with no associated dementia or major
cognitive decline [10,11]. However, Aβ and Tau together
are often associated with dementia [12] and Tau mutations
and/or accumulation are causal to some neurodegenerative
diseases that do not display β-amyloid pathology, including
FTDP-17, PSP, and CBD, suggesting that Tau associated
neurodegeneration can occur independently of plaque
deposition [6,7]. Taken together, these clinical findings sup-
port our hypothesis that Tau may be a critical modulator of
Aβ1-42 toxicity through autophagic clearance of toxic
intracellular Aβ1-42 [13], which may be secreted when
autophagy fails, leading to extracellular plaque deposits.
In conclusion, loss of normal Tau function may alter
microtubule stability and affect the execution of autophagy.
Figure 6 Tau deletion attenuates Aβ1-42-induced cell death. Cupric silver staining of 20 μm thick coronal sections in WT mice injected with
lentiviral A) Aβ1-42 + DMSO, B) Aβ1-42 + Nilo, C) Aβ1-42 + Tau + DMSO, D) Aβ1-42 + Tau + Nilo and E) LacZ + DMSO. Silver staining in Tau−/− mice
injected with lentiviral F) Aβ1-42 + DMSO, G) Aβ1-42 + Nilo, H) Aβ1-42 + Tau + DMSO, I) Aβ1-42 + Tau + Nilo and J) LacZ + DMSO. Histograms represent
K) stereological quantification of silver-positive cells and L) caspase-3 activity. Asterisk is significantly different to Aβ1-42 + DMSO or as indicated, bars
are mean ± SEM, two-way ANOVA.
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agy is essential and elevated autophagic activity is beneficial
for neurons to prevent accumulation of protein aggregates
[33-36]. The current studies demosntrate that Tau is
required to mediate the beneficial effects of autophagic
clearance. Boosting autophagy was shown to reduce free
unbound p-Tau and spare microtubule associated protein
Tau in models of neurodegeneration [14,37]. The current
studies suggest that Tau function regulates intracellu-
lar Aβ1-42 clearance and affects extracellular plaque
deposition.
Methods
Primary hippocampal neuronal culture
Fetal WT hippocampal tissue (gestation E15) were dis-
sected and gently triturated with a fire-polished Pasteur
pipette, and the resulting pool of dissociated cells were
plated in 35-mm dishes precoated with polyethyleneimine
(1 mg/ml) (MP Biomedicals NC-N19544450) containing
0.5 ml basal growth medium, which was supplemented
with 5% horse serum and 0.5% fetal calf serum and
replaced with fresh medium every three days. DIV 14 or
when the density of cells reached 3×104 cells, neurons
were infected with 3 μl lentiviruses for 24 hrs and then
treated with 10 μM Nilotinib (AMN-107, NC0604306,
SELLECK CHEMICAL LLC) or 1 μL DMSO for 24 hrs or
100 nM Bafilomycin-A1(AC32812-0001, Acros Organics)
or 20 μM MG132 (NC9819784, Cayman Chemicals) for
6 hrs.
Stereotaxic injection
Lentiviral constructs driving LacZ, human WT Tau and/
or Aβ1-42 were stereotaxically injected at 1×106 multipli-
city of infection (MOI) into the right CA1 hippocampus
of 1 year old male C57BL/6 or Tau−/− as we previously
explained [14,18]. All procedures were approved by the
Georgetown University Animal Care and Use Committee
(GUACUC). Nilotinib was dissolved in DMSO and a total
volume of 30 μl was I.P. injected once a day for 3 weeks.
Half the animals received DMSO and the other half
received Nilotinib in DMSO.
WB analysis
To extract the soluble protein fraction, brain tissue or
cells were isolated and homogenized in 1× STEN buffer
(50 mM Tris (pH 7.6), 150 mM NaCl, 2 mM EDTA,
0.2% NP-40, 0.2% BSA, 20 mM PMSF and protease
cocktail inhibitor), centrifuged at 10,000 g for 20 min at
4°C and the supernatant containing the soluble protein
fraction was collected. To extract insoluble Aβ1-42, the
pellet was re-suspended in 30% formic acid and centri-
fuged at 10,000 g for 20 min at 4°C and the supernatant
was collected. Extracts were analyzed by WB on SDS
NuPAGE 4-12% Bis-Tris gel (Invitrogen, NP0301BOX).β-actin was probed (1:1000) with polyclonal antibody
(ThermoScientific, PA121167). Autophagy antibodies,
including Beclin-1 (1:1000) and LC3-B (1:1000) were
used to probe according to autophagy antibody sampler
kit (Cell Signaling, Inc. Cat# 4445). Tau antibodies were
used as we previously described [14,18]. WBs were
quantified by densitometry using Quantity One 4.6.3
software (Bio Rad).
IHC of brain sections
Animals were deeply anesthetized with a mixture of (1:8)
Xylazine (Edgewood Pharmacy, 20130822) and Ketamine
(Butler Animal Health Supply, 023061), washed with 1×
saline for 1 min and then perfused with 4% (PFA) para-
formaldehyde (MP Biomedicals, ICN15014601) for 15–
20 min. Brains were quickly dissected out and
immediately stored in 4% PFA for 24 hrs at 4°C and then
transferred to 30% sucrose at 4°C for 48 h. Tissues were
cut using a cryostat at 4°C into 20 μm thick sections and
stored at −20°C. Cupric silver and immuno-staining were
performed as we previously described [14,18].
Stereological methods were applied by a blinded inves-
tigator using unbiased stereology analysis (Stereologer,
Systems Planning and Analysis, Chester, MD) to determine
the total positive cell counts in 20 cortical/hippocampal
fields on at least 10 brain sections (~400 positive cells per
animal) from each animal.
Quantification of plaque load or counting plaque num-
ber was performed by a blind investigator using ImageJ by
drawing a line around individual plaques within 1 mm2
radius of 6 randomly selected hippocampal and cortical
regions in 6E10 stained slides. The number of plaques was
averaged per mm2 and compared between treatment
condition, as we previously described [14,18].
Subcellular fractionation for isolation of autophagic
compartments
A total of 0.5 g of animal brains were homogenized at low
speed (Cole-Palmer homogenizer, LabGen 7, 115 Vac) in
1× STEN buffer and centrifuged at 1,000 g for 10 min to
isolate the supernatant from the pellet. The pellet was
re-suspended in 1× STEN buffer and centrifuged once
to increase the recovery of lysosomes. The pooled
supernatants were then centrifuged at 100,000 rpm for
1 hr at 4°C to extract the pellet containing autophagic
vacuoles (AVs) and lysosomes. The pellet was re-suspended
in 10 ml (0 .33 g/ml) 50% Metrizamide (Acros Organics,
AC22943-0250) and 10 ml in cellulose nitrate tubes. A
discontinuous Metrizamide gradient was constructed in
layers from bottom to top as follows: 6 ml of pellet
suspension, 10 ml of 26%; 5 ml of 24%; 5 ml of 20%; and
5 ml of 10% Metrizamide [38]. After centrifugation at
10,000 rpm for 1 hr at 4°C, the fraction floating on the
10% layer (Lysosome) and the fractions banding at the
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inter-phases were collected by a syringe and examined.20S proteasome activity assay
Human M17 neuroblastoma cells were co-transfected
with 3 μg Tau, LacZ or Aβ1-42 cDNAs for 24 hrs and
then treated with 10 μM Nilotinib for additional 24 hrs
(48 hrs total). Either 20 μM proteasomal inhibitor MG132
or 100nM autophagy inhibitor Bafilomycin-A1 were
applied for 6 hrs prior to the beginning of proteasome
activity assays. Cell extracts (100 μg) were incubated
with 250 μM of the fluorescent 20S proteasome specific
substrate Succinyl-LLVY-AMC (Enzo Life Sciences,
BML-P802-0005) at 37°C for 2 hrs. The medium was dis-
carded and proteasome activity was measured in tissue
homogenatesAβ and p-Tau enzyme-linked immunosorbent assay (ELISA)
Specific p-Tau ser396 (Invitrogen, KHB7031) and Aβ1–42
(Invitrogen, KHB3442,) ELISA were performed according
to manufacturer’s protocol as described [15,19]. Caspase-3
activity assays were performed according to manufacturer’s
protocol as we previously described [14,18].Statistical analysis
Data were analyzed with GraphPad software (GraphPad
Prism, CA) using two-way ANOVA. The number of experi-
ments and p values are indicated in the text.
qRT-PCR in primary hippocampal neuronal culture was
performed on Real-time OCR system with Fast SYBR-
Green PCR master Mix (Applied Biosystems, NC0381818)
in triplicate from reverse-transcribed cDNA from mouse
primary cortical neurons injected with lentiviral LacZ, Tau
and/or Aβ1-42 (24 hrs) treated with DMSO or Nilotinib
(24 hrs) using the same primers that were utilized to clone
human Aβ1-42 [13] or Tau [19] into the lentivirus. Gene
expression values were normalized using GADPH levels.Additional file
Additional file 1: Figure S1. To verify equal expression of lentiviral
clones, 20 μm thick coronal brain sections were stained human specific
A) Aβ1-42 and B) V5 and C) merged figure showing that both LacZ and
Aβ1-42 were co-expressed. Endogenous phosphorylated Tau using D)
AT8 and E) V5 and I) merged figure showing LacZ expression. Lentiviral
epitope G) V5 and H) AT8 and I) merged figure showing that both LacZ and
Tau were co-expressed. Human specific J) Aβ1-42, K) AT8 and L) merged
figure shows that Tau and of Aβ1-42 were co-expressed. Histograms
represent M) densitometry of Beclin-1 relative to actin and LC3-II relative
to LC3-I in WT and Tau−/− mice. Asterisk is significantly different to
Aβ1-42 + DMSO, bars are mean ± SEM, two-way ANOVA.Competing interests
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